Dentsply Sirona (XRAY) Q1 2026 earnings review
Turnaround Investments Crush Margins While U.S. Weakness Persists
Dentsply Sirona's Q1 2026 results expose the painful reality of its 'Return-to-Growth' strategy: near-term profitability is being sacrificed for long-term restructuring. While total reported revenue stabilized to flat (+0.1% YoY), constant currency sales fell 6.7%, dragged by a massive 24.2% collapse in the Americas Orthodontic & Implant business. The bottom line bore the brunt of the transformation, with Adjusted EBITDA margins compressing 430 basis points to 14.7% and Adjusted EPS plummeting 39%. Management reiterated FY26 guidance, confirming that 2026 will remain a heavy investment year with continued earnings deceleration before any structural recovery takes hold.
🐂 Bull Case
Management's promise to shift back to a multi-channel dealer strategy is bearing fruit. The company secured a new agreement with Atlanta Dental Supply and successfully installed its first CEREC system under the recently signed Benco Dental partnership.
Despite weakness elsewhere, the Asia Pacific region generated 2.7% constant currency growth across the business, with Essential Dental Solutions and Wellspect Healthcare leading the charge.
🐻 Bear Case
The costs of the turnaround are hitting hard. Adjusted Gross Margin dropped 560 basis points YoY (to 50.7%), and Adjusted EBITDA margin contracted from 19.0% to 14.7%, reflecting negative operating leverage and investment timing.
The Orthodontic and Implant Solutions segment in the Americas is in freefall, dropping 24.2% YoY in constant currency, proving that the U.S. turnaround has yet to find the bottom.
⚖️ Verdict: 🔴
Bearish. The 'Return-to-Growth' plan may be moving forward operationally, but the financial data shows a company still bleeding heavily in its core high-margin segments and geography. With margins compressing and EPS down nearly 40%, the execution risks remain extremely high.
Key Themes
Americas Segment Continues to Hemorrhage
The weakness in the U.S. market, a massive focal point in 2025, has not subsided. Total constant currency sales in the Americas fell 10.7% YoY in Q1 2026. The damage is concentrated in the Orthodontic and Implant Solutions (OIS) segment, which plummeted an alarming 24.2% CC. Essential Dental Solutions in the Americas also lagged, down 8.5% CC. Reorganizing the U.S. commercial team has yet to yield stabilization.
Profitability Under Severe Pressure
Decelerating. Management warned in late 2025 that 2026 would be a heavy investment year, and Q1 data proves it. Adjusted EBITDA margin compressed to 14.7% from 19.0% a year ago. Gross margins suffered an equally severe blow, down from 53.0% to 48.5% (GAAP), driven by restructuring costs, transformation investments, and likely unfavorable product mix as high-margin Implants underperformed.
Dealer Network Re-engagement Generating Early Wins
Following management's strategic pivot to reverse its direct-to-market failures and rebuild bridges with major distributors, Q1 offered tangible progress. The company finalized a new agreement with Atlanta Dental Supply to push its Connected Technology Solutions (CTS). More importantly, they logged their first CEREC system installation under the new Benco Dental agreement, an early milestone in repairing U.S. equipment sales channels.
AI Integration into Diagnostic Software
Dentsply is moving aggressively to monetize its software ecosystem. The company launched Smart View-Detect, an FDA-cleared and CE-marked AI diagnostic tool designed to identify periapical radiolucencies (PARL) in CBCT scans. This reinforces their theme of connecting digital dentistry to clinical workflows, aiming to drive software stickiness and recurring revenue.
New Capital Allocation Strategy Taking Shape
After abruptly eliminating the dividend in 2025 to free up $128 million annually, the company is executing its new capital framework. Priorities are now debt reduction, liquidity management, and working capital improvements. Operating cash flow improved notably to $40M in Q1 (from $7M a year ago) due to favorable accounts receivable collections, though Free Cash Flow remained slightly negative at $(12)M.
Other KPIs
Accelerating. Up sharply from $9 million in the prior year quarter. This line item reflects the severe medicine management is applying, absorbing $60M related to the 2026 restructuring plan, global ERP system rollout, and severance, depressing GAAP operating income to a $(35) million loss.
Decelerating. A supposedly stable consumables segment posted a disappointing 7.2% CC decline globally, weighted down by a 10.5% drop in EMEA and an 8.5% drop in the Americas, offsetting a 12.6% surge in APAC. This raises questions about baseline patient volumes or potential market share losses to low-cost competitors.
Guidance
Stable compared to prior guidance, but represents a deceleration from FY25's reported $3.68 billion. This confirms management's expectation that top-line recovery will not materialize meaningfully in 2026 as the U.S. business undergoes intense restructuring.
Stable compared to prior guidance, but represents an ~9% decline from FY25's $1.60. Earnings are contracting as savings from the $120M restructuring program are heavily reinvested into R&D and clinical education, suppressing near-term profitability.
Key Questions
Americas Ortho & Implants Floor
With the Americas OIS segment declining 24% in constant currency this quarter, have we found the floor, or should we expect double-digit declines to persist through the first half of the year?
Margin Bridge for the Remainder of 2026
Given the 430 basis point contraction in Adjusted EBITDA margin in Q1, how much of this was front-loaded transformation investment versus structural gross margin deterioration? What is the cadence for margin improvement throughout the year to hit the EPS guidance?
Dealer Channel Cannibalization
As the Benco and Atlanta Dental Supply agreements ramp up, are you seeing additive equipment volume, or is it primarily shifting volume that would have otherwise been sold direct?